Free tool
FAERS Monitor: Dawnzera (Autoinjector)
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219407 or its brand name (Dawnzera (Autoinjector), Donidalorsen Sodium). Reports on generic versions are filed under their own applications.
Reports
506
Serious
55
11% of reports
Hospitalization
32
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hereditary angioedema215
- injection site pain41
- headache31
- injection site erythema27
- injection site bruising20
- nausea19
- abdominal distension18
- fatigue18
- dizziness17
- peripheral swelling17
- abdominal pain15
- malaise13
- swelling13
- diarrhoea12
- upper respiratory tract infection12
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 5 |
| 2026 | 501 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,653 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hereditary angioedemaSignal | 215 | 849.8 | 766.5 | 177,886 |
| upper respiratory tract infectionSignal | 12 | 10.8 | 6.2 | 97 |
| injection site bruisingSignal | 20 | 10.4 | 6.8 | 162 |
| injection site erythemaSignal | 27 | 9.0 | 6.3 | 186 |
| abdominal distensionSignal | 18 | 7.2 | 4.6 | 90 |
| swellingSignal | 13 | 5.8 | 3.4 | 47 |
| injection site painSignal | 41 | 5.6 | 4.1 | 151 |
| peripheral swellingSignal | 17 | 4.6 | 2.9 | 44 |
| abdominal painSignal | 15 | 2.7 | 1.6 | 14 |
| headacheSignal | 31 | 2.1 | 1.5 | 16 |
| dizziness | 17 | 1.4 | 0.9 | 2 |
| malaise | 13 | 1.2 | 0.7 | 0 |
| nausea | 19 | 1.0 | 0.6 | 0 |
| fatigue | 18 | 1.0 | 0.6 | 0 |
| diarrhoea | 12 | 0.8 | 0.4 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.